September 2024New Federal Awards |
||||||||||||||||||||||||||||
Georgina Aldridge | Neurology | NIH RF1 3 years |
Vulnerability of the ascending arousal network to alpha-synuclein pathology | |||||||||||||||||||||||||
Zuhair Ballas | Internal Medicine | NIH S10 1 year |
Imaging Cytometer (Equipment for Flow Cytometry) | |||||||||||||||||||||||||
Ruth Chimenti - Contact PI Kathleen Sluka - MPI James Holmes - MPI |
NIH R61 2 years |
Development of diagnostic and prognostic ultrasound imaging biomarkers for plantar heel pain | ||||||||||||||||||||||||||
Daniel Cook | Internal Medicine | NIH K08 5 years |
Inhibiting CD4+ Th2 development and function by CFTR activity | |||||||||||||||||||||||||
Camille Dunn-Johnson | Otolaryngology | NIH R01 5 years |
The Effectiveness of Cochlear Implants in Real-World Settings for Mild Cognitive Impairment and Dementia in Older Adults with Age-Related Hearing Loss | |||||||||||||||||||||||||
John Engelhardt | Anatomy and Cell Biology | NIH N92 4 years |
National Ferret Resource & Research Center on Lung Disease - Federal Contract | |||||||||||||||||||||||||
Alicia Gerke - Contact PI Alejandro Pezzulo - MPI |
Internal Medicine | NIH R56 1 year |
The Role of Residential Bioaerosol Exposure in Pulmonary Sarcoidosis | |||||||||||||||||||||||||
Matthew Hoffman | Otolaryngology | NIH R03 2 years |
Characterizing the impact of presbyphonia on social interaction | |||||||||||||||||||||||||
Allison Momany | Pediatrics | NIH R00 3 years |
Neonatal Stress in Very Preterm Infants: Longitudinal Effects on Epigenetics and Neurodevelopment | |||||||||||||||||||||||||
Christopher Petkov | Neurosurgery | NIH U01 5 years |
Laminar Circuit Motifs for Working Memory and Language: From Cells to Systems | |||||||||||||||||||||||||
Alexandra Petrucci | Neuroscience & Pharmacology | NIH F32 2 years |
Lesion extent and seizure propagation pathways across acute infection and chronic epilepsy in an infection induced mouse model | |||||||||||||||||||||||||
Andrea Weber | Psychiatry | US Dept of Health & Human Services 3 years |
The Substance Use Disorder Training Expansion to Advance Multidisciplinary Services in Iowa (SUD-TEAMS-IA) | |||||||||||||||||||||||||
Aaron Scherer | Internal Medicine | US Dept of Health & Human Services, CDC 5 years |
UI Advancing Research in Immunization Services Network Coordinating Center (Contact PI is in the College of Public Health and the award sits there as well) | |||||||||||||||||||||||||
Competitive Renewal |
||||||||||||||||||||||||||||
Stephanie Radke | OBGyn | Iowa Dept of Health & Human Services 6 years |
Maternal Health Innovation | |||||||||||||||||||||||||
Other Awards |
||||||||||||||||||||||||||||
Chandrikha Chandrasekharan | Internal Medicine | AstraZeneca LP | Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01) | |||||||||||||||||||||||||
David Dickens | Pediatrics | Merck Sharp & Dohme LLC | Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors | |||||||||||||||||||||||||
Nabeel Hamzeh - Contact PI Karin Hoth - MPI |
Internal Medicine | Ann Theodore Foundation | The Neurobiology of Cognitive Dysfunction in Patients with Sarcoidosis. | |||||||||||||||||||||||||
Mariia Kumskova | Internal Medicine | Hemostasis & Thrombosis Research Society | Mechanism of bleeding in Ehlers-Danlos syndrome | |||||||||||||||||||||||||
Lama Noureddine | Internal Medicine | F. Hoffmann-La Roche Ltd | RO7434656, an antisense inhibitor of complement factor B, in patients with primary IgA nephropathy at high risk of progression | |||||||||||||||||||||||||
Kittika Poonsombudlert | Internal Medicine | Incyte Corporation | A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms | |||||||||||||||||||||||||
Antonio Sanchez | Internal Medicine | 89bio, Inc. | Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ENLIGHTEN-Cirrhosis) | |||||||||||||||||||||||||
Mark Schultz | Pediatrics | University of Notre Dame | Developing mRNA therapeutics and biomarkers for GSD III | |||||||||||||||||||||||||
Adeyinka Taiwo | Internal Medicine | Stanford University | Taiwo K12 - Diabetes-Docs: Physician-Scientist Career Development Program from Stanford | |||||||||||||||||||||||||
Chen Tan | Internal Medicine | Eurofins Viracor, LLC | BK Virus In Renal Transplant | |||||||||||||||||||||||||
Ziying Yan | Anatomy and Cell Biology | University of Kansas Center for Research, Inc. | Development of novel approaches for gene editing therapies of cystic fibrosis | |||||||||||||||||||||||||
Hanna Zembrzuska | Internal Medicine | Novartis Pharmaceuticals Corporation | Rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN) | |||||||||||||||||||||||||
August 2024New Federal Awards |
||||||||||||||||||||||||||||
Zuhair Ballas | Internal Medicine | NIH S10 1 year |
Imaging Cytometer | |||||||||||||||||||||||||
James Byrne | Radiation Oncology | NIH DP2 3 years |
Novel extremophile-inspired radioprotectants | |||||||||||||||||||||||||
Po Hien Ear | Surgery | DoD, CDMRP 2 years |
Targeted approach of Nrf2 inhibition in neuroendocrine cancers | |||||||||||||||||||||||||
Jonah Elliff | Microbiology | NIH F30 4 years |
Evaluating the impact of malaria on immunogenecity of the Ebola virus vaccine | |||||||||||||||||||||||||
Eric Hoffman | Radiology | NIH S10 6 years |
NAEOTOM Alpha Photon-Counting CT Scanner | |||||||||||||||||||||||||
David Kaczka - Contact PI Emmanuel Akor - MPI Daniel Meggo - MPI |
Anesthesia | NSF 1 year |
I-Corps: Translation Potential of a Low-cost Mechanical Ventilator for Underserved Communities | |||||||||||||||||||||||||
Thomas Kehl-Fie | Microbiology | NIH R01 2 years |
Leveraging host-imposed metal starvation to elucidate the molecular and environmental factors that dictate metal utilization by the iron/manganese superoxide dismutase superfamily | |||||||||||||||||||||||||
Filiz Korkmaz | Microbiology | NIH R00 3 years |
Establishing Mechanisms of LOX-1 Dependent Immune Regulation During Pneumonia | |||||||||||||||||||||||||
Hongshuai Li | Orthopedic Surgery | NIH R01 5 years |
Role of FGF21 in DMD | |||||||||||||||||||||||||
Katherine Mathews | Pediatrics | US Dept of Health and Human Services, CDC | Surveillance of Muscular Dystrophies Component A: Iowa MD STARnet Core Site | |||||||||||||||||||||||||
Wendy Maury | Microbiology | NIH UH2 2 years |
Identifying placental tissue tropism and cellular mechanisms of Ebola Virus transmission from mother to fetus in pregnancy | |||||||||||||||||||||||||
Patrick McNamara | Pediatrics | NIH UG3 6 years |
1/2 Milrinone for Prevention of Post-Patent Ductus Arteriosus Closure Syndrome in Extremely Preterm Infants (MIDAS Trial) - CCC | |||||||||||||||||||||||||
Aaron Seaman | Internal Medicine | US Dept of Health and Human Services, CDC 5 years |
University of Iowa Prevention Research Center for Rural Health | |||||||||||||||||||||||||
Jacob Simmering | Internal Medicine | NIH K01 5 years |
Remote monitoring using commercially available activity trackers and computer vision provides a holistic, low-cost assessment of Parkinson's disease symptoms | |||||||||||||||||||||||||
Jan Wessel | Neurology | NIH R21 2 years |
The TMS-evoked potential as a measure of cortical excitation and inhibition during cognitive processes | |||||||||||||||||||||||||
Competitive Renewal |
||||||||||||||||||||||||||||
David Stoltz | Internal Medicine | Cystic Fibrosis Foundation | Iowa Cystic Fibrosis Foundation Research & Development Program | |||||||||||||||||||||||||
Other Awards |
||||||||||||||||||||||||||||
Eric Hoffman - Contact PI |
Radiology | University of California San Francisco | SubPopulations and InteRmediate Outcomes in COPD (SPIROMICS) III | |||||||||||||||||||||||||
Douglas Laux |
Internal Medicine | GlaxoSmithKline, Inc. | Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma | |||||||||||||||||||||||||
Merck Sharp & Dohme LLC | Neoadjuvant and adjuvant V940 (mRNA-4157) in combination with pembrolizumab (MK- 3475) versus standard of care, and pembrolizumab monotherapy in participants with resectable locally advanced cutaneous squamous cell carcinoma | |||||||||||||||||||||||||||
Katherine Mathews |
Pediatrics | Larimar Therapeutics, Inc. | Jive: An Open-Label Extension Study to Assess the Long-term Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Subcutaneous CTI-1601 in Subjects with Friedreich's Ataxia | |||||||||||||||||||||||||
Peggy Nopoulos |
Psychiatry | Anonymous - Domestic | Scanlan Scobell Psychedelic Research | |||||||||||||||||||||||||
John Rieth |
Internal Medicine | Ascentage Pharma Group, Inc. | APG-115 as a monotherapy or in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors. | |||||||||||||||||||||||||
Antonio Sanchez |
Internal Medicine | Boehringer Ingelheim Pharmaceuticals, Inc. | Multicenter, randomised, double-blind, placebo-controlled, 48-week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | |||||||||||||||||||||||||
Jodi Tate |
Psychiatry | The Molina Healthcare Charitable Foundation | Project ECHO: Iowa's IDD Complex Care Needs ECHO for Direct Care Professionals | |||||||||||||||||||||||||
Hanna Zembrzuska |
Internal Medicine | Novartis Pharmaceuticals Corporation | Rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cutaneous systemic sclerosis | |||||||||||||||||||||||||
July 2024New Federal Awards |
||||||||||||||||||||||||||||
Amy Conrad | Pediatrics | NIH R01 4 years |
Speech Development and Brain Structure/Function in Infants with Isolated Oral Clefts: Relationship Anesthesia Exposure and Oxygenation | |||||||||||||||||||||||||
Huxing Cui | Neuroscience & Pharmacology | NIH R01 5 years |
Uncovering the role of hypothalamic ciliary cAMP signaling in sex-specific control of metabolic homeostasis | |||||||||||||||||||||||||
Chad Grueter | Internal Medicine | NIH R01 5 years |
Mediator kinase regulation of cardiac transcription | |||||||||||||||||||||||||
Priya Issuree | Internal Medicine | NIH R35 5 years |
Connecting epigenetic programming of T cells with molecular traits of the immune system in health and disease | |||||||||||||||||||||||||
Bradley Jones | Microbiology | NIH R03 2 years |
Influence of an E. coli hyperadherent probiotic on Salmonella intestinal colonization | |||||||||||||||||||||||||
Louis Kolling | Neuroscience & Pharmacology | NIH F32 1 year |
Reversal of Tau Pathology to Rescue Serotonergic Function in Early Alzheimer's Disease | |||||||||||||||||||||||||
Balaji Manicassamy | Microbiology | NIH R01 5 years |
Investigation of host glycan requirements for the transmission of influenza viruses at the human-animal interface | |||||||||||||||||||||||||
Paul McCray | Pedicatrics | NIH R03 1 year |
Impact of ATP-binding cassette A3 (ABCA3) mutations on alveolar type 2 cell function and genetic complementation | |||||||||||||||||||||||||
Mark Schultz | Pediatrics | NIH R35 5 years |
Regulation and Mechanisms of ER Proteostasis | |||||||||||||||||||||||||
Sam Stephens | Internal Medicine | NIH R01 3 years |
Metabolic control of beta-cell secretory organelle function | |||||||||||||||||||||||||
Seth Tomchik | Neuroscience & Pharmacology | DoD, CDMRP 3 years |
Mechanisms of Neuronal Dysregulation Underlying Behavioral Alterations in Neurofibromatosis Type 1 | |||||||||||||||||||||||||
Competitive Renewal |
||||||||||||||||||||||||||||
Steven Lentz - Contact PI Anil Chauhan - MPI |
Internal Medicine | NIH T32 5 years |
Program in Hematology: Molecular & Cell Biology Blood Cells | |||||||||||||||||||||||||
Matthew Pothoff | Neuroscience & Pharmacology | NIH R01 4 years |
Regulation of Metabolism by FGF21 | |||||||||||||||||||||||||
Daniel Tranel - Contact PI Sheila Baker - MPI Gordon Buchanan - MPI |
Neurology | NIH T32 5 years |
Neuroscience Training Program | |||||||||||||||||||||||||
Other Awards |
||||||||||||||||||||||||||||
Umar Farooq | Internal Medicine | Janssen Research & Development, Inc. | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | |||||||||||||||||||||||||
Paul McCray | Pediatrics | Emily's Entourage | Enhanced Airway Transduction and Therapeutic Cargo Delivery with novel AAV Capsid Variants | |||||||||||||||||||||||||
Mohammed Milhem | Internal Medicine | Replimune, Inc. | A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician's Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen | |||||||||||||||||||||||||
Eric Mou | Internal Medicine | BeiGene USA | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Obinutuzumab in patients with previously untreated chronic Lymphocytic Leukemia | |||||||||||||||||||||||||
Christopher Strouse | Internal Medicine | Janssen Research & Development, Inc. | A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in Combination with Daratumumab SC (Tec-D) Following Induction with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants with Standard-risk Newly Diagnosed Multiple Myeloma | |||||||||||||||||||||||||
Yousef Zakharia | Internal Medicine | Kura Oncology | Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO 2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors | |||||||||||||||||||||||||
Merck & Company, Inc. | A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy | |||||||||||||||||||||||||||
June 2024New Federal Awards |
|
|
|
|||||||||||||||||||||||||
Sarah Beattie |
Pediatrics |
NIH R21 |
HTS with Aspergillus fumigatus for novel, mold-active antifungals |
|||||||||||||||||||||||||
Ruth Chimenti |
Physical Therapy |
DoD, CDMRP |
Expanding and Accelerating Access to Care for Achilles Tendinopathy through Self-management Rehabilitation Strategies |
|||||||||||||||||||||||||
Martine Dunnwald |
Anatomy & Cell Biology |
NSF |
Formation and function of the periderm |
|||||||||||||||||||||||||
Elissa Faro |
Internal Medicine |
NIH R01 |
Can an Evidence-Based Mental Health Intervention be Implemented into Preexisting Home Visiting Programs using Implementation Facilitation? |
|||||||||||||||||||||||||
John Harty |
Pathology |
NIH R01 |
Brain T cell interactions in microbial experienced mice |
|||||||||||||||||||||||||
|
|
NIH R21 |
Brain T cell interactions in microbial experienced mice |
|||||||||||||||||||||||||
Christopher Petkov |
Neurosurgery |
NSF |
Neural Mechanisms for Auditory Memory Sequencing and Prediction |
|||||||||||||||||||||||||
Anjali Sharathkuman |
Pediatrics |
NIH R21 |
Epidemiology and Biosocial risk factors for adverse outcomes of COVID-19 in people with sickle cell disease : Analyses of national COVID surveillance registry |
|||||||||||||||||||||||||
Daniel Tranel |
Neurology |
NIH T32 |
Understanding Health and Disease at the Behavioral-Biomedical Interface |
|||||||||||||||||||||||||
Budd Tucker, Contact PI |
Ophthalmology |
NIH R01 |
Sustained Treatment of Wet AMD |
|||||||||||||||||||||||||
Jessica Tucker |
Microbiology |
NIH R21 |
Gammaherpesviruses induce transfer RNA cleavage |
|||||||||||||||||||||||||
Other Awards |
||||||||||||||||||||||||||||
James Byrne |
Radiation Oncology |
Dr. Ralph and Marian Falk Medical Research Trust |
Novel materials to improve management of hypoxic tumors |
|||||||||||||||||||||||||
Margaret Byrne |
Internal Medicine |
Merck & Company, Inc. |
Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer |
|||||||||||||||||||||||||
Linda Cadaret |
Internal Medicine |
GB002, Inc. |
PROSERA |
|||||||||||||||||||||||||
Alejandro Comellas Freymond |
Internal Medicine |
Duke University |
RECOVER-AUTONOMIC: A Platform Protocol for Evaluation of Interventions for Autonomic Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) |
|||||||||||||||||||||||||
Marlan Hansen, Contact PI |
Otolaryngology |
M34 Inc. |
Recombinant AAV capsid library screening to identify clinically relevant capsid variants in humans |
|||||||||||||||||||||||||
Markus Kuehn |
Opthalmology |
Boehringer Ingelheim GmbH |
AMPK Activation for Neuroprotection in Glaucoma |
|||||||||||||||||||||||||
Douglas Laux |
Internal Medicine |
GlaxoSmithKline LLC |
Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck |
|||||||||||||||||||||||||
Lama Noureddine |
Internal Medicine |
Amgen, Inc. |
Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis |
|||||||||||||||||||||||||
Tahaunty Pena |
Internal Medicine |
Sanofi US Services Inc. |
Oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung tr |
|||||||||||||||||||||||||
Michael Shy |
Neurology |
Elpida Therapeutics SPC |
A Prospective Natural History and Outcome Meausre Discovery Study of Charcot-Marie-Tooth Disease, Type 4J |
|||||||||||||||||||||||||
Ian Thornell |
Internal Medicine |
Cystic Fibrosis Foundation |
Cellular contributions to HEMT |
|||||||||||||||||||||||||
Praveen Vikas |
Internal Medicine |
Pfizer, Inc. |
PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR BASED THERAPY |
|||||||||||||||||||||||||
Michael Wendt |
Internal Medicine |
Novartis Pharmaceuticals Corporation |
Impact of Hypoxia on Lipid Metabolism in Obesity-Driven Breast Cancer Progression |
|||||||||||||||||||||||||
Hanna Zembrzuska |
Internal Medicine |
Novartis Pharmaceuticals Corporation |
Intravenous secukinumab infusion in adults with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR). |
|||||||||||||||||||||||||
May 2024New Federal Awards |
|
|
|
|||||||||||||||||||||||||
Barry London, Contact PI |
Internal Medicine |
NIH U01 |
Sex-dependent Impairment of Nitric Oxide Signaling and Mitochondrial Metabolism in Radiation-Induced Cardio-Pulmonary Dysfunction |
|||||||||||||||||||||||||
Vincent Magnotta, Contact PI |
Radiology |
NIH R01 |
High Resolution MRSI for Alzheimer's Disease and Related Dementias |
|||||||||||||||||||||||||
Maria Spies |
Biochemistry |
NIH T32 |
Iowa Biotech-TP: Predoctoral Program in Biotechnology |
|||||||||||||||||||||||||
Colette Galet |
Emergency Medicine |
DHHS, Administration on Aging |
Empowering Communities to Deliver and Sustain Evidence-Based Falls Prevention Programs |
|||||||||||||||||||||||||
Hua Sun |
Pediatrics |
NIH R01 |
Targeting dynein-mediated trafficking in diabetic podocytopathy |
|||||||||||||||||||||||||
Rebecca Dodd |
Internal Medicine |
Dod, CDMRP |
Targeted Therapy for MPNST Metastasis |
|||||||||||||||||||||||||
Competitive Renewal |
|
|
|
|||||||||||||||||||||||||
Vanessa Curtis, Contact PI |
Pediatrics |
Iowa DHHS |
Pediatric Mental Health Care Access Program (PMHCAP) |
|||||||||||||||||||||||||
Other Awards |
|
|
|
|||||||||||||||||||||||||
Carol Johnson |
Pediatrics |
Iowa DHHS |
Iowa Newborn Screening (NBS) Propel Project |
|||||||||||||||||||||||||
Grerk Sutamtewagul |
Internal Medicine |
Kura Oncology |
Venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia |
|||||||||||||||||||||||||
|
|
Kura Oncology |
Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia |
|||||||||||||||||||||||||
Douglas Laux |
Internal Medicine |
Regeneron Pharmaceuticals, Inc. |
REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with Cemiplimab in patients with advanced solid tumors. |
|||||||||||||||||||||||||
David Bender |
OBGyN |
GOG Foundation |
NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer |
|||||||||||||||||||||||||
|
|
GOG Foundation |
VB10.16 Alone or in Combination with Atezolizumab in Patients with HPV16-Positive, PD-L1-positive, Recurrent or Metastatic Cervical Cancer who are Refractory to Pembrolizumab with Chemotherapy with/without Bevacizumab |
|||||||||||||||||||||||||
Sam Stephens |
Internal Medicine |
Juvenile Diabetes Research Foundation International |
201311107-FY24 SRA: Role of -cell Golgi dysfunction in Type 1 diabetes pathogenesis |
|||||||||||||||||||||||||
Christopher Strouse |
Internal Medicine |
Janssen Research and Development, LLC |
Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants with High-Risk Multiple Myeloma |
|||||||||||||||||||||||||
April 2024New Federal Awards |
|
|
|
|||||||||||||||||||||||||
Jing Jiang |
Pediatrics |
NIH R01 |
Mapping a Causal Prefrontal Pathway for Amygdala Modulation Utilizing Invasive and Noninvasive Brain Stimulation and Recording Methods in Humans |
|||||||||||||||||||||||||
Marco Hefti |
Pathology |
NIH R01 |
A non-canonical role for tau in early human brain development |
|||||||||||||||||||||||||
Budd Tucker |
Ophthalmology |
NIH R21 |
Label-free microfluidic isolation of patient iPSC-derived photoreceptor cells |
|||||||||||||||||||||||||
Steven Offer |
Pathology |
NIH R01 |
A precision medicine approach to improve prediction of severe toxicity in fluorouracil chemotherapy |
|||||||||||||||||||||||||
Competitive Renewals |
|
|
|
|||||||||||||||||||||||||
George Richerson |
Neruology |
NIH R01 |
Inhibition of central CO2 chemoreception by seizures: Effects on ventilation, cardiovascular control and postictal recovery of consciousness |
|||||||||||||||||||||||||
Other Awards |
|
|
|
|||||||||||||||||||||||||
Alejandro Comellas Freymond |
Internal Medicine |
KUMC |
All of Us Research Program - Heartland Consortium |
|||||||||||||||||||||||||
Erin Shriver |
Ophthalmology |
Immunovant Sciences, GmbH |
Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED) |
|||||||||||||||||||||||||
Yousef Zakharia |
Internal Medicine |
Astellas Pharma Global Development, Inc |
Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED) |
|||||||||||||||||||||||||
Hanna Zembrzuska |
Internal Medicine |
ImmPACT Bio USA, Inc. |
IMPT-514 in participants with active, refractory lupus nephritis and systemic lupus erythematosus |
|||||||||||||||||||||||||
David Bushnell |
Radiology |
RayzeBio, Inc. |
RYZ101 in combination with carboplatin + etoposide + atezolizumab in subjects with somatostatin receptor expressing (SSTR+) extensive stage small cell lung cancer (ES-SCLC) |
|||||||||||||||||||||||||
Christopher Strouse |
Internal Medicine |
Janssen Research & Development, Inc |
JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma |
|||||||||||||||||||||||||
Tracey Cho |
Neurology |
Sanofi US Services, Inc |
Frexalimab (SAR441344) to Terifluomide (Aubagio) in Adult Participants with Relapsing Forms of Multiple Sclerosis |
|||||||||||||||||||||||||
|
|
Sanofi US Services, Inc |
Frexalimab (SAR441344) to Placebo in Adult Participants with Nonrelapsing Secondary Progressive Multiple Sclerosis |
|||||||||||||||||||||||||
Katherine Mathews |
Pediatrics |
Avidity Biosciences, Inc |
AOC 1044 Administered Intravenously to Healthy Adults |
|||||||||||||||||||||||||
Val Sheffield |
Pediatrics |
CRISPR Therapeutics, Inc |
MYOC gene editing for Myocilin Associated Glaucoma |
|||||||||||||||||||||||||
March 2024New Federal Awards |
|
|
|
|||||||||||||||||||||||||
Sandra Blom |
Internal Medicine |
NIH F31 |
GRASP55 Regulates Pancreatic Beta-cell Golgi Structure and Function During Cytokine Stress |
|||||||||||||||||||||||||
Songhai Chen, Contact PI |
Neuroscience & Pharmacology |
NIH R01 |
Role of the CTLH E3 ubiquitin ligase in breast cancer progression |
|||||||||||||||||||||||||
Carl Andrew Frank |
Anatomy & Cell Biology |
NIH R01 |
Synaptic defects caused by Mitochondrial Complex I dysfunction |
|||||||||||||||||||||||||
Stephanie Gantz |
Physiology |
NIH R01 |
Regulation of monoamine neurons by delta glutamate receptors |
|||||||||||||||||||||||||
Lyndsay Harshman |
Pediatrics |
DoD, CDMRP |
Women's Health in Tuberous Sclerosis Complex: A Population Based Assessment of Morbidity to Inform Clinical Care |
|||||||||||||||||||||||||
Miriam McDonough |
Neuroscience & Pharmacology |
NIH F31 |
Investigating the molecular mechanisms underlying aldosterone-mediated sodium appetite |
|||||||||||||||||||||||||
Scott Moye-Rowley |
Physiology |
NIH R21 |
Novel mechanisms of azole resistance in clinical isolates of Candida glabrata |
|||||||||||||||||||||||||
Krystal Parker |
Psychiatry |
NIH R21 |
Roles of Descending Forebrain Pathways to the Cerebellum in Behavioral Timing |
|||||||||||||||||||||||||
Mark Schultz |
Pediatrics |
NIH R03 |
Investigating the importance of liver-specific glycans on NPC1 proteostasis |
|||||||||||||||||||||||||
Hanna Stevens |
Psychiatry |
NIH R01 |
Adolescent Insecticide Exposure and ADHD Risk: Mechanisms of Immediate Effects and Ongoing Vulnerability |
|||||||||||||||||||||||||
Stefan Strack |
Neuroscience & Pharmacology |
DoD, CDMRP |
Identifying temporal and spatial origins and reversibility in mouse models of neurodevelopmental disorders with autism |
|||||||||||||||||||||||||
Ajit Vikram |
Internal Medicine |
NIH R01 |
Glycopeptide vancomycin reshapes gut microbiota to mediate cardioprotective effects via microRNA-204 |
|||||||||||||||||||||||||
Jason Wilken |
Physical Therapy |
DoD, CDMRP |
The Effects of Heel Clearance on Foot Loading with Carbon Fiber Custom Dynamic Orthoses |
|||||||||||||||||||||||||
Competitive Renewals |
|
|
|
|||||||||||||||||||||||||
Julien Sebag |
Physiology |
NIH R01 |
Investigating the requirement of MRAP2 for ghrelin function |
|||||||||||||||||||||||||
Maria Spies |
Biochemistry |
NIH R35 |
Assembly and Dynamics of Molecular Machines in Genome Maintenance |
|||||||||||||||||||||||||
Other Awards |
|
|
|
|||||||||||||||||||||||||
John Bernat |
Pediatrics |
Denali Therapeutics |
DNL126 in pediatric participants with mucopolysaccharidosis type IIIA (Sanfilippo Syndrome Type A) |
|||||||||||||||||||||||||
Marina Del Rios, Contact PI |
Emergency Medicine |
Robert Wood Johnson Foundation 2 years |
Innovation and Measurement of Pre-emptive Action on Racial Justice and Health Equity Curriculum Teaching (IMPACT) |
|||||||||||||||||||||||||
Mohammed Milhem |
Internal Medicine |
Polaris Pharmaceuticals, Inc. |
Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial |
|||||||||||||||||||||||||
Antonio Sanchez |
Internal Medicine |
GlaxoSmithKline, Inc. |
GSK4532990 in Adults with pre-cirrhotic Non-Alcoholic Steatohepatitis (NASH) |
|||||||||||||||||||||||||
Lane Strathearn |
Pediatrics |
EarliTec Diagnostics, Inc. |
Dynamic Quantification of Social-Visual Engagement (DQSVE) in Autism Spectrum Disorder (ASD): Diagnosis and Assessment For Children Ages 31 - 84 Months. |
|||||||||||||||||||||||||
Christopher Strouse |
Internal Medicine |
Juno Therapeutics, Inc. |
BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma |
|||||||||||||||||||||||||
Grerk Sutatewagul |
Internal Medicine |
Merk Sharp & Dohme, LLC |
Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) |
|||||||||||||||||||||||||
Tomohiro Tanaka |
Internal Medicine |
Takeda Development Center Americas, Inc. |
Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis |
|||||||||||||||||||||||||
Budd Tucker |
Ophthalmology |
Gilbert Famiy Foundation |
Development of novel next generation model systems for study and treatment of NF1 |
|||||||||||||||||||||||||
Yousef Zakharia |
Internal Medicine |
Arsenal Biosciences |
AB-2100 in patients with recurrent advanced or metastatic clear-cell renal cell carcinoma. |
|||||||||||||||||||||||||
February 2024New Federal Awards |
|
|
|
|||||||||||||||||||||||||
Michael Anderson, Contact PI |
Physiology, |
NIH R01 |
Foundational Biology of Glaucoma GWAS Loci |
|||||||||||||||||||||||||
Denice Hodgson-Zingman, Contact PI |
Internal Medicine |
NIH R01 |
A New Pacing Approach for Cardiac Conditioning and Enhanced Cardioprotection |
|||||||||||||||||||||||||
Emily Adelizzi |
Anatomy & Cell Biology |
NIH F31 |
Deciphering a tissue specific role for Arhgap29 during palatogenesis |
|||||||||||||||||||||||||
Damian Krysan |
Pediatrics |
NIH R01 |
REgulation of Candida albicans Pathogenesis by Protein Kinase and Transccription Factor |
|||||||||||||||||||||||||
Sarah Short |
Internal Medicine |
NIH K01 |
Antioxidant regulation of intestinal homeostasis and disease |
|||||||||||||||||||||||||
Other Awards |
|
|
|
|||||||||||||||||||||||||
Don Andrson |
Orthopedic Surgery |
Arthritis Foundation |
Determining the traumatic origins of ankle OA and the time to joint degeneration |
|||||||||||||||||||||||||
Tracey Cho |
Neurology |
Genetech, Inc. |
Satralizumab in patients with anti-n-methyl D aspartic acid receptor (NMDAR) or anti-leucine rich glioma inactivated 1 (LGI1) |
|||||||||||||||||||||||||
Prajwal Dhakal |
Internal Medicine |
Nerviano Medical Sciences, S.r.l. |
A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML |
|||||||||||||||||||||||||
Douglas Laux |
Internal Medicine |
Hoosier Cancer Research Network, Inc. |
A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (HCRN MCC20-443; iPRRT Study) |
|||||||||||||||||||||||||
Melinda Seering |
Anesthesia |
Haisco-USA Pharmaceuticals, Inc. |
A Global Multicenter, Randomized, Double-blinded, Propofol controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HSK3486 Injectable Emulsion for Induction of General Anesthesia in Adults Undergoing Elective Surgery |
|||||||||||||||||||||||||
Saima Sharif |
Internal Medicine |
PDD Investigator Services, LLC |
A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer |
|||||||||||||||||||||||||
January 2024New Fedaral Awards: |
|
|
|
|
||||||||||||||||||||||||
Patrick Sinn, Contact PI Paul McCray, MPI |
Pediatrics |
NIH R01 |
Adenine Base Edited Correction of Cystic Fibrosis Airways |
|||||||||||||||||||||||||
Lane Strathearn |
Pediatrics |
NIH R01 |
Perinatal Experience and Epigenetic Change in Autism: Discovering Modifiable Pathways for Intervention |
|||||||||||||||||||||||||
Michael Tomasson |
Internal Medicine |
US National Science Foundation |
I-Corps: A Home-based Solution for Remote Lung Function Monitoring for Patients with Chronic Lung Disease |
|||||||||||||||||||||||||
Other Awards: |
|
|
|
|||||||||||||||||||||||||
Ted Abel |
Neuroscience & Pharmacology |
Eagles Autism Foundation |
Characterizing the functional impact of mutations in Nr4a2-related Neurodevelopmental Syndrome |
|||||||||||||||||||||||||
Huxing Cui |
Novo Nordisk Pharmaceuticals, Inc |
Novo Nordisk Pharmaceuticals, Inc |
Neural basis of metabolic control by ciliary cAMP signaling |
|||||||||||||||||||||||||
Alina Dumitrescu |
Ophthalmology |
Janssen Research & Development, Inc. |
Global Patient Registry of Inherited Retinal Diseases |
|||||||||||||||||||||||||
Rami El Abiad |
Internal Medicine |
Sanofi US Services Inc. |
Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants with Eosinophilic Esophagitis (EoE) |
|||||||||||||||||||||||||
Umar Farooq |
Internal Medicine |
Janssen Research & Development, Inc. |
Global Patient Registry of Inherited Retinal Diseases |
|||||||||||||||||||||||||
Mark Granner |
Neurology |
Neurona Therapeutics, Inc |
A First-in-human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE) |
|||||||||||||||||||||||||
Jon Houtman |
Microbiology |
Roy J. Carver Charitable Trust |
State-of-the-art multicolor cellscape imaging system by canopy biosciences. |
|||||||||||||||||||||||||
Asad Javed |
Internal Medicine |
IDEAYA Biosciences Inc. |
IDE196 (Darovasertib) in combination with Crizotinib versus investigator's choice of treatment as a first-line therapy in HLA-A2 negative metastatic uveal melanoma (DAR-UM-2) |
|||||||||||||||||||||||||
Douglas Laux |
Internal Medicine |
Regeneron Pharmaceuticals, Inc. |
A multicenter, open-label phase 2 study of intratumoral vidutolimod (CMP-001) in combination with inravenous cemiplimabin subjects with selected types of advanced or metastatic cancer. |
|||||||||||||||||||||||||
Paul McCray |
Pediatrics |
Cystic Fibrosis Foundation |
005651G223 Adenine Base Editing Repair of a CFTR Nonsense Mutation |
|||||||||||||||||||||||||
Mohammed Milhem |
Internal Medicine |
Merck Sharp & Dohme LLC |
Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma |
|||||||||||||||||||||||||
Dawn Quelle, Contact PI |
Neuroscience & Pharmacology, |
Gilbert Family Foundation |
Improving Immunotherapy in MPNSTs |
|||||||||||||||||||||||||
Ziying Yan |
Anatomy & Cell Biology |
Cystic Fibrosis Foundation |
Developing Basal Cell Tropic Human Bocavirus for Applications in Airway Gene Editing |
|||||||||||||||||||||||||
Yousef Zakharia |
Internal Medicine |
Bristol-Myers Squibb Company |
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors |
|||||||||||||||||||||||||
|
Notable & novel scientific awards to celebrate.
2023: January, February, March, April, May, June, July, August, September, October, November, December
December 2023 New Federal Awards: |
|
|
|
Sanjana Dayal |
Internal Medicine |
NIH R01 |
Preventive mechanisms of Age-associated Thrombosis |
John Fingert, Contact PI |
Ophthalmology |
NIH R21 |
Stem cell approaches to normal tension glaucoma |
Robert Piper, Contact PI |
Physiology |
NIH R33 |
Towards systematic analysis of cardiac voltage-gated sodium channel beta subunit Function |
Eric Taylor |
Physiology |
NIH R01 |
Regulation of Hepatic Fuel Fluxes by the Mitochondrial Dicarboxylate Carrier |
Mary Weber |
Microbiology |
NIH R61 |
Development of genetic tools for overexpression and targeted mutagenesis of Orientia tsutsugamushi TPR proteins |
Competitive Awards: |
|
|
|
Enrique Leira |
Neurology |
NIH U24 |
The University of Iowa's Regional Stroke Research Network |
|
|
|
|
Stephanie Chen |
Pathology |
Exact Sciences Corporation |
Specimen Collection Study to Evaluate Biomarkers in Subjects with Cancer |
Nabeel Hamzeh |
Internal Medicine |
Bristol-Myers Squibb Company |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis |
Markus Kuehn |
Ophthamology |
Animal Eye Consultants of Iowa |
Adaptive Immune Responses Contributing to Canine Glaucoma |
Delwyn Miller |
Psychiatry |
University of Southern California |
Alzheimer's Disease Neuroimaging Initiative (ADNI4) |
Amy Ryan |
Anatomy and Cell Biology |
Children's Hospital of Los Angeles |
Development of a model that integrates inflammation and tissue injury to predict and mitigate the post-acute sequelae of COVID-19 |
Michael willey |
Orthopedics |
MEND Nutrition, Inc. |
MENDTM Clinical Trial Proposal |
November 2023 New Federal Awards: |
|
|
|
Yi Huang |
Internal Medicine |
NIH R01 |
Role of LSD1 in Triple Negative Breast Cancer Development and Therapeutic Response |
Competitive Awards: |
|
|
|
Stanley Perlman |
Microbiology |
NIH R01 |
Role of LSD1 in Triple Negative Breast Cancer Development and Therapeutic Response |
Other Awards: |
|
|
|
Umar Farooq |
Internal Medicine |
Cargo Therapeutics |
An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CART-cell |
Umar Farooq |
Internal Medicine |
Janssen Research & Development, Inc. |
A Phase 1b Multicenter, Open-label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non- Hodgkin Lymphoma |
Philip Gander, Contact PI |
Radiology, Neurosurgery |
REAM Foundation, |
Novel Investigation of Brain Mechanisms for Different Triggers in Misophonia |
Dilek Ince |
Internal Medicine |
Corixa Corporation |
A Phase 2b, randomized, controlled, open-label study to evaluate the immune response and safety of the RSVPreF3 OA investigational vaccine in adults (50 years of age) when administered to lung and renal transplant recipients comparing 1 versus 2 doses an |
Annie Killoran |
Nurology |
Genetech, Inc. |
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study To Evaluate The Safety, Biomarkers, And Efficacy Of Tominersen In Individuals With Prodromal And Early Manifest Huntington's Disease |
Douglas Laux |
Internal Medicine |
Replimune, Ltd. |
A Phase 2, Open-label, Multicenter Study Investigating RP3 in Combination with Other Therapy in Patients with Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck |
Douglas Laux |
Internal Medicine |
Seagen, Inc. |
A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors |
Mohammed Milhem |
Internal Medicine |
Seagen, Inc. |
A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors |
Sneha Phadke |
Internal Medicine |
AstraZeneca Pharmaceuticals LP |
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/ |
Chen Tan |
Internal Medicine |
Ansun Biopharma, Inc. |
A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS 181 for the Treatment of Lower Respiratory Tract Parain:fluenza Infection in Immunocompromised Subjects |
Yousef Zakharia |
Internal Medicine |
Worldwide Clinical Trials, Inc. |
A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM -RESISTANT OVARIAN CARCINOMA, ENDOMETRIAL ADENOCARCINOMA, AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS |
October 2023 New Federal Awards: |
|
|
|
James Byrne |
Radiation Oncology |
NIH K08 |
Exploiting Carbon Monoxide Biofoams to Radio-Sensitize Rectal Cancer Cells While Protecting Normal Bowel |
Grace Ciampa |
Internal Medicine |
NIH F31 |
Examining the Function of a Novel Protein in the Cardiac Junctional Membrane Complex |
Competitive Awards: |
|
|
|
Thomas Scholz |
Pediatrics |
Iowa Department of Human Services |
MHDS 24-008 Community Circle of Care |
Kirill Nourski |
Neurosurgery |
University of Wisconsin-Madison |
Mechanisms of Loss, Recovery and Disorders of Consciousness |
Other Awards: |
|
|
|
Ernesto Ruiz Duque |
Internal Medicine |
Bristol-Myers Squibb Company |
DISCOVER-HCM |
Rami El Abiad |
Internal Medicine |
Celldex Therapeutics, Inc. 3 years |
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis |
Andrew Russo |
Molecular Physics & Biophysicis |
Seattle Institute for Biomedical and Clinical Research |
Role of Sleep Disruption after mTBI as a Driver of Chronic Post-Traumatic Headache |
Alejandro Comellas Freymond |
Internal Medicine |
IQVIA RDS Inc. |
A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1) |
Muhammad Furqan |
Internal Medicine |
AbbVie, Inc. |
A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors. |
Muhammad Furqan |
Internal Medicine |
BeiGene USA |
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors |
Muhammad Furqan |
Internal Medicine |
Poseida Therapeutics, Inc. |
A PHASE 1 DOSE ESCALATION AND EXPANDED COHORT STUDY OF P-MUC1C-ALLO1 IN ADULT SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS |
David Axelrod |
Surgery |
CTI Clinical Trial Services, Inc. |
An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA 99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standa |
Sneha Phadke |
Internal Medicine |
NSABP Foundation, Inc. |
CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or |
Carla Nester |
Pediatrics |
Apellis Pharmaceuticals, Inc. |
AN OPEN-LABEL, NONRANDOMIZED, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PEGCETACOPLAN IN PARTICIPANTS WITH C3 GLOMERULOPATHY OR IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS |
Patrick Sinn |
Pediatrics |
Cystic Fibrosis Foundation |
005661G223 Base-Editing for Life-Long Correction of CF Airways |
Vishnu Mani |
Surgery |
Direct Biologics, LLC |
Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles for Hospitalized Patients with Moderate-to-Severe ARDS: A Phase III Clinical Trial |
Eric Hoffman |
Radiology |
Imperial College London |
THE BLF EARLY COPD DEVELOPMENT PARTNERSHIP GRANT |
Brian Link |
Internal Medicine |
Mayo Clinic |
Characteristics and outcomes of patients with Diffuse Large B-cell Lymphoma Receiving Frontline Treatment at Cancer Centers within the LEO Cohort, ML43785 |
September 2023 New Federal Awards: |
|
|
|
John Fingert, Contact PI |
Ophthalmology |
NIH R01 |
Genetic Factors for Glaucoma in the OHTS; Risk, Progression and Mechanism |
Aloysius Klingelhutz |
Microbiology |
NIH R21 |
The role of ISG15 and ISGylation in the senescence-associated secretory phenotype |
Elizabeth Newell |
Pediatrics |
NIH R01 |
Mechanisms of type I interferon neuropathology following traumatic brain injury |
Jon Houtman |
Microbiology |
NIH R25 |
R25 YES: Cancer Research Opportunities at Iowa |
Competitive Awards: |
|
|
|
Milan Sonka, Contact PI |
Radiation Oncology |
NIH R56 |
Deep LOGISMOS |
Vincent Magnotta, Contact PI |
Radiology, |
NIH R01 |
Cerebellar metabolism, neural circuits, and symptoms in bipolar disorder |
Other Awards: |
|
|
|
Umar Farooq |
Internal Medicine |
Angiocrine Bioscience, Inc. |
Angiocrine Long Term Follow-Up Umbrella Study |
Umar Farooq |
Internal Medicine |
Nektar Therapeutics |
A PHASE 2/3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NKTR-255 VS PLACEBO FOLLOWING CD19-DIRECTED CAR-T CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA |
Bruce Gantz |
Otolaryngology |
Cochlear Americas |
Preliminary Evaluation of a Dexamethasone Eluting Electrode Array |
Marlan Hansen |
Otolaryngology |
Julius Clinical Research B.V. |
A Natural History Study in Individuals with Otoferlin Gene (OTOF)-Mediated Hearing Loss |
Annie Killoran |
Neurology |
Worldwide Clinical Trials, Inc. |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (G |
Antonio Sanchez |
Internal Medicine |
Merck Sharp & Dohme LLC |
A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis |
Antonio Sanchez |
Internal Medicine |
PPD Investigator Services, LLC |
A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease |
Christopher Strouse |
Internal Medicine |
Poseida Therapeutics, Inc. |
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma (MM) |
August 2023 New Federal Award: |
|
|
|
Alexander Boyden |
Pathology |
NIH R01 |
Pathogenic B cell:CD4 T cell interactions in a novel B cell-dependent EAE mouse model of multiple sclerosis |
Sean Fain |
Radiology |
NIH R01 |
Dynamic Imaging of Lung Ventilation and Perfusion Using CT and MRI |
Gena Ghearing |
Neurology |
CDC |
Expanding epilepsy self-management support in healthcare networks (EXPAND) |
Aleksander Lenert |
Internal Medicine |
NIH K23 |
Investigating Disease Activity, Bone Damage and Interleukin-1 Genes in Adult SAPHO Syndrome and Chronic Nonbacterial Osteomyelitis |
Yi Luo |
Urology |
DOD, CDMRP |
CP220038 - Development of a novel DNA aptamer-based IFN-y targeted therapy for chronic cystitis pain |
Wendy Maury, Contact PI |
Microbiology |
NIH UH2 |
Defining the effect of Plasmodium infection on Ebola virus vaccine efficacy |
Ben Miskle |
Pharmacy Practice and Science |
SAMHSA H79 |
Iowa Naloxone Expansion and Training (IA-NEXT) |
Catherina Pinnaro |
Pediatrics |
NIH K23 |
Hyperglycemia in Turner syndrome: Mechanisms and X chromosome contributions |
Matthew Potthoff |
Neuroscience & Pharmacology |
NIH R01 |
Therapeutic Potential of FGF21 for Alzheimer's Disease |
Brett Faine, Contact PI |
Emergency Medicine |
NIH R21 |
Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial |
Seth Tomchik |
Neuroscience & Pharmacology |
NIH R01 |
Dopaminergic circuit modulation of learning and arousal-mediated memory enhancement |
Elliott Sohn, Contact PI |
Ophthalmology, |
NIH R01 |
MMP-9 based immune-driven mechanisms of neovascular AMD |
Competitive Awards: |
|
|
|
Marlan Hansen, Contact PI |
Otolaryngology |
NIH R01 |
Reduction of Intracochlear Trauma and Fibrosis Using Dual Network, Zwitterionic Hydrogel Thin Films on Cochlear Implant Surfaces |
Robert Mullins, Contact PI |
Ophthlamology |
NIH R01 |
Choriocapillaris Protection and Replacement in AMD |
Other Awards: |
|
|
|
David Bender |
OBGyn |
GOG Foundation |
Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FR-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, |
James Byrne |
Radiation Oncology |
V Foundation for Cancer Research |
Overcoming immunotherapy resistance using oxygen-entrapping materials |
Marcelo Correia |
Internal Medicine |
Lilly USA, LLC |
A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4) |
Umar Farooq |
Internal Medicine |
ImmPACT Bio USA Inc. |
A PHASE 1/2 MULTI-CENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF IMPT-314, A CD19/20 BISPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA |
Muhammad Furqan |
Internal Medicine |
AGRESSIVE B-CELL NON HODGKIN LYMPHOMA |
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304) |
Muhammad Furqan |
Internal Medicine |
Elicio Therapeutics, Inc. |
First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS viral oncogene homolog (NRAS) Mutated Solid Tumors |
Hillel Haim |
Microbiology |
ViiV Healthcare |
Computational platform to personalize Fostemsavir treatment to people living with HIV-1 |
Asad Javed |
Internal Medicine |
Lyell Immunopharma, Inc. |
A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults with Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies |
Mohammed Milhem |
Internal Medicine |
Merck Sharp & Dohme LLC |
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE- 010) |
Sneha Phadke |
Internal Medicine |
Arvinas Estrogen Receptor Inc. |
An Open-Label, Randomized, Non-Comparative Phase 2 Study of ARV-471 or Anastrozole in Post-Menopausal Women With ER+/HER2- Breast Cancer in the Neoadjuvant Setting |
Philip Polgreen |
Internal Medicine |
Pfizer, Inc |
Developing approaches to estimate a more accurate measure of the burden of influenza |
Ernesto Ruiz Duque |
Internal Medicine |
Bristol-Myers Squibb Company |
ODYSSEY-HCM |
Lucy Wibbenmeyer |
Surgery |
PolyNovo Biomaterials Pty Ltd. |
Pivotal Study to Assess the Safety and Effectiveness of NovoSorb Biodegradable Temporizing Matrix (BTM) in the Treatment of Severe Burn Skin Injuries |
July 2023 New Federal Awards: |
|
|
|
Alexandra Bova |
Neurology |
NIH F32 |
Nigrostriatal dopamine mechanisms of cognitive control |
Martine Dunnwald |
Anatomy & Cell Biology |
NIH R03 |
Popliteal Pterygium syndrome, IRf6, and the periderm |
Adam Dupuy |
Anatomy & Cell Biology |
US DoD, CDMRP |
ME220036 Identification of genetic mechanisms driving transition of benign nevi to malignant melanoma |
Oliver Gramlich |
Ophthlamology |
NIH R03 |
Targeting Cholesterol Homeostasis to maintain vision in MS-like optic neuritis |
Xiaoyang Hua |
Otolaryngology |
NIH R01 |
The nose-lung cross talk in upper respiratory virus infection induced asthma exacerbations |
Miles Pufall |
Biochemistry & Molecular Biology |
US National Science Foundation |
NSF/MCB-BSF: The effect of transcription factor binding on UV lesion accumulations |
Chen Tan |
Internal Medicine |
NIH R01 |
NK cell responses to JC polyomavirus |
Tomohiro Tanaka |
Internal Medicine |
US DoD, CDMRP |
Estimating the Causal Effect of Liver Allocation Policy Reflecting the Heterogeneity from Age and Geography |
Kristina Thiel |
OBGyn |
US DoD, CDMRP |
CA220729P1 - Progestin therapy for endometrial cancer |
Other Awards: |
|
|
|
Loreen Herwaldt |
Internal Medicine |
University of Wisconsin-Madison |
Povidone-iodine to Stop Access-Related Infections and Transmission of Staphylococcus Aureus (PAINTS) |
Katie Larson Ode |
Pediatrics |
Worldwide Clinical Trials, Inc. |
A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients with Acquired Hypothalamic Obesity |
Kelly Mulfaul |
Ophthalmology |
BrightFocus Foundation |
Investigating Human Choroidal Macrophage Recruitment and Activation in Age-related Macular Degeneration - Mulfaul 2022 - BrightFocus |
Sneha Phadke |
Internal Medicine |
Olema Pharmaceuticals, Inc. |
A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination with the CDK4/6 Inhibitor Ribociclib or with the PI3K Inhibitor Alpelisib in Adult Subjects with Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer |
Donna Santillan, Contact PI |
OBGyn |
Heartland Health Research Alliance, LTD |
Heartland |
Tomohiro Tanaka |
Internal Medicine |
PPD Investigator Services, LLC |
Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in HBeAg-negative Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1) |
George Weiner |
Internal Medicine |
V Foundation for Cancer Research |
T cell help and resistance to anti-cancer monoclonal antibody therapy |
Yousef Zakharia |
Internal Medicine |
Astellas Pharma Global Development, Inc. |
A Phase 1 Study of ASP1002 in Participants with Metastatic or Locally Advanced Solid Tumors |
Yousef Zakharia |
Internal Medicine |
AstraZeneca LP |
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients I |
June 2023 New Federal Awards: |
|
|
|
Marina Del Rios |
Emergency Medicine |
NIH R01 |
Dime la VerDAD - Verify, Debunk, and Disseminate |
Joel Geerling |
Neurology |
NIH R01 |
Brainstem cold-defense circuitry |
Corinne Griguer |
Radiation Oncology |
NIH R01 |
Mitochondria electron transport chain complexes adaptative responses to cellular stress |
John Harty |
Pathology |
NIH R21 |
Regulating Pathogen-induced Protective and Pathogenic CD8 T cells in the CNS |
Diana Jalal, Contact PI |
Internal Medicine, |
NIH R01 |
The Alternative Pathway of Complement: A Potential Contributor to Adverse Outcomes in CKD |
Benjamin Kelvington |
Neuroscience & Pharmacology |
NIH F31 |
Defining the molecular impact of 16p11.2 deletion on reward response in striatal dopamine receptor D1-expressing neurons |
Scott Lieberman |
Pediatrics |
NIH R01 |
Tyk2 and Associated Cytokines in Salivary Gland Autoimmunity |
Allison Momany |
Pediatrics |
NIH K99 |
Neonatal Stress in Very Preterm Infants: Longitudinal Effects on Epigenetics and Neurodevelopment |
Andrew Sullivan |
Neuroscience & Pharmacology |
NIH F31 |
The Role of IRX3 Neurons in the Regulation of Body Weight Homeostasis |
Other Awards: |
|
|
|
Ted Abel |
Neuroscience & Pharmacology |
George Mason University |
Estradiol signaling pathways mediating sex differences in striatal synaptic plasticity |
Sabarish Ayyappan |
Internal Medicine |
Mayo Clinic |
Randomized phase 2 study with safety run-in of PD-1 inhibitor and IgG4 SIRP-Fc fusion protein (TTI-622) and PD-1 inhibitor and IgG1 SIRP-Fc fusion protein (TTI-621) in relapsed Diffuse Large B-Cell Lymphoma (DLBCL) |
Chandrikha Chandrasekharan |
Internal Medicine |
Astellas Pharma, Inc |
A Phase 1/1b study of ASP2074 in participants with Metastatic or Locally Advanced solid tumors |
Rami El Abiad |
Internal Medicine |
Ellodi Pharmaceuticals, L.P. |
Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Randomized, Double-blind, Placebo-Controlled 24-Week Induction Study of APT-1011, followed by a Single-arm Open-label Extension, in Adult Subjects with Eosinophilic |
Muhammad Furqan |
Internal Medicine |
Tempus Labs, Inc. |
TEMPUS GEMINI NSCLC SURVEILLANCE STUDY |
Jeremy Greenlee |
Neurosurgery |
Massachusetts Eye & Ear Infirmary |
Next-generation clinical phenotyping and pathophysiology of laryngeal dystonia and voice tremor, Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor (Project 3) |
Serena Gumusoglu |
OBGyn |
Burroughs Wellcome Fund |
Next Gen Pregnancy Initiative |
Patrick McGonagill |
Surgery |
CSL Behring LLC |
CSL Behring TAP Study |
Jacob Michaelson |
Psychiatry |
Columbia University |
Triangulation of missense variant impact through multimodal modeling and functional assays |
Sneha Phadke |
Internal Medicine |
PSI Pharma Support America, Inc. |
An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer (ELECTRA) |
Andrea Swenson |
Neurology |
Massachusetts General Hospital |
An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with Amyotrophic Lateral Sclerosis |
Richard Tyler |
Otolaryngology |
Sage Therapeutics, Inc. |
AN OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF BREXANOLONE IN THE TREATMENT OF ADULT PARTICIPANTS WITH TINNITUS |
May 2023 New Federal Awards: |
|
|
|
Bryan Allan, Contact PI |
Radiation Oncology |
NIH R21 |
Redox manipulation of iron to improve glioblastoma therapy: A phase 1 trial |
Polly Ferguson, Contact PI |
Pediatrics |
NIH K12 |
CTSA K12 PROGRAM AT THE UNIVERSITY OF IOWA |
Donna Santillan |
ObGyn |
NIH R25 |
Beginning and Early Stage Translational (BEST) Researchers |
Seth Tomchik |
Neuroscience & Pharmacology |
NIH R01 |
Mechanisms of Nf1 Pathophysiology Underlying Hyperactivity |
Ergun Uc, Contact PI |
Neurology, |
NIH RF1 |
Linear predictive coding of EEG Activity for Diagnosis of Parkinson's Disease (LEAD-PD) |
Competitive Awards: |
|
|
|
Bruce Gantz |
Otolaryngology |
NIH P50 |
Iowa Cochlear Implant Clinical Research Center VIII |
Other Awards: |
|
|
|
Chandrikha Chandrasekharan |
Internal Medicine |
Pharmaceutical Research Associates |
A randomised, open-label, Phase II, dose/schedule optimisation study of NUC-3373/leucovorin/irinotecan plus bevacizumab (NUFIRI-bev) versus 5-FU/leucovorin/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients with previously treated... |
Alicia Gerke |
Internal Medicine |
Merck Sharp & Doheme LLC |
INSIGNIA-COPD |
Marlan Hansen |
Otolaryngology |
Akouos, Inc |
A Phase 1/2 Trial of AAVAnc80-hOTOF Gene Therapy in Individuals with Sensorineural Hearing Loss due to Biallelic Otoferlin Gene (OTOF) Mutations |
Tahaunty Pena |
Internal Medicine |
Renovion, Inc. |
A Phase 3 Open-Label, Randomized, Standard of Care-controlled Parallel Arm Study to Demonstrate Efficacy and Safety of ARINA-1 in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) Progression in Participants with Bilateral Lung Tr |
Andrea Swenson |
Neurology |
Massachusetts General Hospital |
HEALEY ALS Platform Trial, Task 12 |
Michael Tomasson |
Internal Medicine |
Pfizer, Inc. |
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA |
Douglas Van Daele |
Otolaryngology |
Nyxoah SA |
ACCCESS Study - A multicenter study to assess the safety and effectiveness of the Genio dual-sided hypoglossal nerve stimulation system for the treatment of obstructive sleep apnea in subjects with complete concentric collapse of the soft palate. |
Patricia Winokur |
Internal Medicine |
Pfizer, Inc |
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE |
April 2023 New Federal Awards: |
|
|
|
Mahmoud Abou Alaiwa |
Internal Medicine |
NIH R01 |
Contribution of Small Airways to Mucociliary Transport Dysfunction |
Hillel Haim |
Microbiology |
NIH R01 |
Predicting HIV-1 escape from therapeutics in vitro and in vivo - toward personalizing medicine for people living with HIV |
Vincent Magnotta |
Radiology |
NIH S10 |
University of Iowa - 7T Small Animal MRI Upgrade |
Robert Roghair |
Pediatrics |
NIH R01 |
Sedentary behavior, physical activity, and 24-hour behavior in pregnancy and offspring health: the Pregnancy 24/7 Offspring Study |
Robert Roghair |
Pediatrics |
NIH T35 |
Iowa Medical Student Summer Research Program in trans-NIDDK Research |
Seth Tomchik |
Neuroscience & Pharmacology |
NIH R01 |
Genetic and molecular mechanisms of Nf1-dependent neuronal regulation of metabolism |
Aislinn Williams |
Psychiatry |
Dod, CDMRP |
AR220030_Validating tRNA viruses to target SCN2A-related autism phenotypes |
Competitive Awards: |
|
|
|
Tarah Colaizy |
Pediatrics |
NIH UG1 |
NICHD Cooperative Multicenter Neonatal Research Network |
Peggy Nopoulos, Contact PI |
Psychiatry |
NIH T32 |
The Iowa Neuroscience Specialty Program in Research Education (INSPIRE) |
Patrick Sinn |
Pediatrics |
NIH R01 |
Life-long phenotypic correction of CF airways |
Other Awards: |
|
|
|
Sabarish Ayyappan |
Internal Medicine |
Kite Pharma, Inc. |
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) |
Chandrikha Chandrasekharan |
Internal Medicine |
Pfizer, Inc. |
A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EVIDENCE OF ANTI-TUMOR ACTIVITY OF PF-07284892 (ARRY-558) AS A SINGLE |
Umar Farooq |
Internal Medicine |
Kure.ai |
CASE2422 A phase 1 single arm, open label study to evaluate the safety of UF-KURE19 cells in patients with relapsed or refractory B cell non-Hodgkin lymphomas. |
Muhammad Furqan |
Internal Medicine |
AstraZeneca Pharmaceuticals LP |
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line |
Steven Lentz |
Internal Medicine |
Novo Nordisk, Inc |
Frontier 4 |
Steven Lentz |
Internal Medicine |
Novartis Pharmaceuticals Corporation |
A PHASE 1B, OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALPN-303 IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4) |
Janet Pollard |
Radiology |
Novartis Pharmaceuticals Corporation |
PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate |
Erin Shriver |
Opthalmology |
Viridian Therapeutics, Inc |
A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN-001, A Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED) |
March 2023 New Federal Awards: |
|
|
|
Zuhair Ballas |
Internal Medicine |
NIH S10 |
Full Spectrum Cell Sorter Flow Cytometer |
Maya Evans |
Psychiatry |
NIH F21 |
Cellular and molecular investigations of striatal enlargement |
Marlan Hansen, Contact PI |
Otolarygology, |
NIH UM1 |
University of Iowa Institute for Clinical and Translational |
Robert Roghair |
Pediatrics |
NIH T35 |
Medical Student Summer Research Program |
Maria Spies, Contact PI |
Biochemistry & Molecular |
NIH R21 |
Natural products inhibitors targeting homology-directed DNA |
Stefan Strack |
Neuroscience, |
NIH R21 |
Interplay between tau and PKA condensates in ADRD |
Seth Tomchik |
|
NIH R01 |
Mechanisms of compartmentalized plasticity in learning and memory |
Competitive Awards: |
|
|
|
David Gordon |
Pediatrics |
NIH R37 |
Gene expression signature based screening in Ewing sarcoma |
Jia Luo |
Pathology |
NIH R01 |
Endoplasmic Reticulum Stress and Alcohol neurotoxicity |
David Weiss, Contact PI |
Mirobiology |
NSF |
REU Site: Microbiology at the host-pathogen interface |
Other Awards: |
|
|
|
John Bernat |
Pediatrics |
Sanofi US Services, Inc |
A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Double-Dummy, Active-Comparator Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients with Gaucher Disease Type 3 (GD3) Who have Reached Therapeutic Goals w |
Muhammad Furqan |
Internal Medicine |
Immunocore Limited |
A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers |
Katherine Mathews |
Pediatrics |
Virginia Commonwealth University |
GRASP-01-002- Defining Clinical Endpoints in Becker Muscular Dystrophy |
Praveen Vikas |
Internal Medicine |
Pharmaceutical Research Associates |
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in |
Daniel Berg |
Internal Medicine |
Astellas Pharma Global Development, Inc |
A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Panc |
Tomohiro Tanaka |
Internal Medicine |
PPD Investigator Services, LLC |
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis |
Alejandro Comellas Freymond |
Internal Medicine |
AstraZenica AB |
A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). |
Antonio Sanchez |
Internal Medicine |
Zydus Therapeutics Inc |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects with Primary Biliary Cholangitis |
Andrea Swenson |
Neurology |
Massachusetts General Hospital |
HEALEY ALS Platform Trial, Task # 11 |
Steven Polyak |
Internal Medicine |
TriNetX |
A Retrospective Observational Study of the Standard of Care, and Medical and Surgical Treatment Patterns in Crohn's Perianal Fistulas (CPF) in the U.S. |
February 2023 New Federal Awards: |
|
|
|
Ernesto Fuentes |
Biochemistry |
NIH R01 |
Molecular Mechanisms Regulating Bacterial Two-component Signaling Systems |
Kristin Claflin |
Neuroscience & Pharmacology |
NIH K01 |
Regulation of neuronal function by mitochondrial uncoupling |
Georgina Aldridge |
Neurology |
NIH R01 |
Cortical Alpha-Synuclein in Dementia |
Markus Kuehn |
Ophthalmology |
NIH R01 |
T-cell mediated RGC damage in glaucoma |
Damian Krysan |
Pediatrics |
NIH R21 |
Systematic Genetic Analysis of C. albicans CNS Infection |
Competitive Awards |
|
|
|
Noah Butler |
Microbiology |
NIH R01 |
Development and function of CD4+ memory T cells during malaria |
Noah Butler |
Microbiology |
NIH R01 |
Regulation of Plasmodium-specific CD4+ T cells |
Richard Smith - Contact PI |
Otolaryngology, Pediatrics, |
NIH R01 |
C3 Glomerulopathy - A Collaborative Study |
Alexander Bassuk |
Pediatrics |
NIH K12 |
Molecular and Cellular Research to Advance Child Health |
Other Awards |
|
|
|
Ferhaan Ahmad |
Internal Medicine |
Cytokinetics, Inc |
SEQUOIA-HCM OLE |
Stephan Arndt |
Psychiatry |
Northeast Iowa Behavioral Health |
Evaluation project: Certified Community Behavioral Health Clinic Planning, Development, and Implementation Grant (CCBHC) |
John Bernat |
Pediatrics |
AVROBIO, Inc |
A Follow-Up Study of Subjects with Type 1 Gaucher Disease Who Previously Received AVR-RD-02 |
Linda Cadaret |
Internal Medicine |
Acceleron Pharma, Inc |
SOTERIA: An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH |
Chandrikha Chandrasekharan |
Internal Medince |
CG Pharmaceuticals, Inc |
A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemoth |
Rami El Abiad |
Internal Medince |
AstraZenica Pharmaceuticals LP |
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis |
Umar Farooq |
Internal Medince |
PRA Health Sciences |
Long-term Follow-up Protocol for Subjects Treated with Adicet Allogeneic Gamma Delta () CAR T Cell Investigational Products |
Asad Javed |
Internal Medince |
Replimune, Inc |
An Open-Label, Multicenter, Phase 1 Study of RP3 as a Single Agent and in Combination with PD-1 Blockade in Patients with Solid Tumors |
Douglas Laux |
Internal Medince |
Incyte Biosciences Internal S.a.r.l. |
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS 1) Recurrent/Metastatic Squamous Cell Carci |
Margarida Magalhaes-Silverman |
Internal Medince |
Equillium, Inc. |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease |
Varun Monga |
Internal Medince |
Medpace Clinical Research, LLC |
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma |
Lama Noureddine |
Internal Medince |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy Trial of Sibeprenlimab in the Treatment of Immunogl |
Stefan Strack, Contact PI |
Neuroscience & Pharmacology |
Eagles Autism Foundation |
Primary PKA Dysregulation in Marbach-Schaaf Neurodevelopmental Syndrome |
Patricia Winokur |
Internal Medince |
Pfizer, Inc. |
A PHASE 1/2 RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS |
January 2023 New Federal Awards: |
|
|
|
Bao Vu |
Molecular Physiology & Biophysics |
NIH R21 |
Functional and transcriptome analyses of protein kinases in Candida glabrata antifungal drug resistance |
Brandon Davies |
Biochemistry & Molecular Biology |
NIH R01 |
Regulation of Endothelial Lipase and HDL Metabolism by ANGPTL3 |
Chris Ahern, Contact PI |
Molecular Physiology & Biophysics |
NIH R01 |
A Versatile Chemical-Genetic Approach to Determine Bases for Arrhythmogenesis and Sodium Channelopathies |
Chris Ahern |
Molecular Physiology & Biophysics |
NIH R35 |
Chemical Biology of Voltage-Gated Cation Channels |
David Stoltz |
Internal Medicine |
NIH T32 |
Climate Change and Lung Health Training Program |
Enrique Leira, Contact PI |
Neurology & Internal Medicine |
NIH U01 |
The University of Iowa Stroke Preclinical Assessment Network to Support Translational Studies for Acute Cerebroprotection |
Kevin Legge |
Pathology |
NIH R01 |
Protection and Immunity after Polyanhydride Nanoparticle Vaccination against Avian Influenza A Virus |
M Washington |
Biochemistry & Molecular Biology |
NIH R35 |
Structural and mechanistic studies of DNA bypass pathways in eukaryotes |
Nikolai Artemyev |
Molecular Physiology & Biophysics |
NIH R01 |
Molecular underpinnings of photoreceptor transcriptional regulation by CRX and NRL |
Santiago Ortega Gutierrez |
Neurology |
NIH R03 |
Novel risk stratification score for patients with acute Cerebral Venous Thrombosis |
Other Awards: |
|
|
|
Brian Link |
Internal Medicine |
Mayo Clinic (Prime: Genetech) |
Characteristics and Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) at Least Two Prior Lines of Systemic Therapy and Treated at Cancer Centers Within the LEO Cohort |
Chandrikha Chandrasekharan |
Internal Medicine |
Pfitzer, Inc |
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF PF-07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07265028 IN PARTICIPANTS |
Christopher Strouse |
Internal Medicine |
ICON Clinical Research, LLC (Prime: Takeda) |
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients with Multiple Myeloma |
Douglas Hornick |
Internal Medicine |
AN2 Therapeutics |
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease |
Frank Faraci |
Internal Medicine |
LeDucq Foundation |
Brain Endothelium: A Nexus for Cerebral Small Vessel Disease |
Grerk Sutamtewagul |
Internal Medicine |
Pharmaceutical Research Associates (Prime: Gilead Sciences) |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia |
Jon Houtman |
Cancer Center |
American Cancer Society |
Iowa Cancer Research Experience (ICARE) |
Katherine Mathews |
Pediatrics |
Asklepios BioPharmaceutical, Inc. |
A two-part multicenter study: a randomized, double-blind, placebo-controlled dose-escalation safety and bioavailability phase (Part 1) followed by double-blind, placebo-controlled, adaptive phase (Part 2) study to evaluate the safety and efficacy of LION- |
Katherine Mathews |
Pediatrics |
Lexeo Theraputics |
A Phase 1/2 Study of the Safety and Efficacy of LX-2006 Gene Therapy in Friedreich's Ataxia |
Michael Ohl |
Internal Medicine |
Iowa Department of Public Health (Prime: SAMHSA) |
The Integrated Addiction Care Coordination and Essential Support Services (iACCESS) |
Muhammad Furqan |
Internal Medicine |
Amgen, Inc. |
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment |
Rami El Abiad |
Internal Medicine |
Celgene International II SARL LC |
A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS |
Saima Sharif |
Internal Medicine |
GlaxoSmithKline LLC |
Phase II, Single Arm Study of Neoadjuvant Dostarlimab (TSR-042) in Stage II and III Deficient Mismatch Repair Colon Cancers |
Seth Tomchik |
Neurosciences & Pharmacology |
Texas A&M University (Prime: NIH) |
The role of Nf1 in sleep-dependent regulation of metabolic function |
Umar Farooq |
Internal Medicine |
Caribou Biosciences, Inc. |
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) |
Varun Monga |
Internal Medicine |
C4 Therapeutics, Inc. |
Phase1/2 open-label multicenter study to characterize the safety and tolerability of CFT8634 in subjects with locally Advanced or Metastatic SMARCB1 perturbed cancers Including Synovial Sarcoma and SMARCB1-Deleted Solid Tumors |
Xingshen Sun |
Anatomy & Cell Biology |
Cystic Fibrosis Foundation |
004590G222 Early life impact of CFTR modulators on the endocrine pancreas and diabetes in CF |
|
|
|
Visit the Archives Page for previous awards.